Grand Pharmaceutical Group Dividends and Buybacks
Dividend criteria checks 3/6
Grand Pharmaceutical Group is a dividend paying company with a current yield of 6.16% that is well covered by earnings.
Key information
6.2%
Dividend yield
0.01%
Buyback Yield
| Total Shareholder Yield | 6.2% |
| Future Dividend Yield | 6.9% |
| Dividend Growth | 25.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | HK$0.260 |
| Payout ratio | 38% |
Recent dividend and buyback updates
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, 512 has been paying a dividend for less than 10 years.
Growing Dividend: 512's dividend payments have increased, but the company has only paid a dividend for 6 years.
Dividend Yield vs Market
| Grand Pharmaceutical Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (512) | 6.2% |
| Market Bottom 25% (HK) | 3.3% |
| Market Top 25% (HK) | 8.0% |
| Industry Average (Pharmaceuticals) | 4.0% |
| Analyst forecast (512) (up to 3 years) | 6.9% |
Notable Dividend: 512's dividend (6.16%) is higher than the bottom 25% of dividend payers in the Hong Kong market (3.32%).
High Dividend: 512's dividend (6.16%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.01%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (37.7%), 512's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (62.8%), 512's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 22:43 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Grand Pharmaceutical Group Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Yiling Chen | Guosen Securities Co., Ltd. |